Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network
Background & aims: Ashwagandha (Withania somnifera) is widely used in Indian Ayurvedic medicine. Several dietary supplements containing ashwagandha are marketed in the US and Europe, but only one case of drug-induced liver injury (DILI) due to ashwagandha has been published. The aim of this case...
Published in: | Liver International |
---|---|
Main Authors: | , , , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/1805/29858 |
id |
ftiupui:oai:scholarworks.indianapolis.iu.edu:1805/29858 |
---|---|
record_format |
openpolar |
spelling |
ftiupui:oai:scholarworks.indianapolis.iu.edu:1805/29858 2024-09-09T19:46:50+00:00 Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network Björnsson, Helgi K. Björnsson, Einar S. Avula, Bharathi Khan, Ikhlas A. Jonasson, Jon G. Ghabril, Marwan Hayashi, Paul H. Navarro, Victor Medicine, School of Medicine 2020-04 application/pdf https://hdl.handle.net/1805/29858 en_US eng Wiley 10.1111/liv.14393 Liver International Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829. doi:10.1111/liv.14393 https://hdl.handle.net/1805/29858 Publisher Policy PMC Liver Drug-Induced Liver Injury Dietary Supplements Article 2020 ftiupui https://doi.org/10.1111/liv.14393 2024-08-08T03:18:32Z Background & aims: Ashwagandha (Withania somnifera) is widely used in Indian Ayurvedic medicine. Several dietary supplements containing ashwagandha are marketed in the US and Europe, but only one case of drug-induced liver injury (DILI) due to ashwagandha has been published. The aim of this case series was to describe the clinical phenotype of suspected ashwagandha-induced liver injury. Methods: Five cases of liver injury attributed to ashwagandha-containing supplements were identified; three were collected in Iceland during 2017-2018 and two from the Drug-Induced Liver Injury Network (DILIN) in 2016. Other causes for liver injury were excluded. Causality was assessed using the DILIN structured expert opinion causality approach. Results: Among the five patients, three were males; mean age was 43 years (range 21-62). All patients developed jaundice and symptoms such as nausea, lethargy, pruritus and abdominal discomfort after a latency of 2-12 weeks. Liver injury was cholestatic or mixed (R ratios 1.4-3.3). Pruritus and hyperbilirubinaemia were prolonged (5-20 weeks). No patient developed hepatic failure. Liver tests normalized within 1-5 months in four patients. One patient was lost to follow-up. One biopsy was performed, showing acute cholestatic hepatitis. Chemical analysis confirmed ashwagandha in available supplements; no other toxic compounds were identified. No patient was taking potentially hepatotoxic prescription medications, although four were consuming additional supplements, and in one case, rhodiola was a possible causative agent along with ashwagandha. Conclusions: These cases illustrate the hepatotoxic potential of ashwagandha. Liver injury is typically cholestatic or mixed with severe jaundice and pruritus, but self-limited with liver tests normalizing in 1-5 months. Article in Journal/Newspaper Iceland Indiana University - Purdue University Indianapolis: IUPUI Scholar Works Indian Liver International 40 4 825 829 |
institution |
Open Polar |
collection |
Indiana University - Purdue University Indianapolis: IUPUI Scholar Works |
op_collection_id |
ftiupui |
language |
English |
topic |
Liver Drug-Induced Liver Injury Dietary Supplements |
spellingShingle |
Liver Drug-Induced Liver Injury Dietary Supplements Björnsson, Helgi K. Björnsson, Einar S. Avula, Bharathi Khan, Ikhlas A. Jonasson, Jon G. Ghabril, Marwan Hayashi, Paul H. Navarro, Victor Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
topic_facet |
Liver Drug-Induced Liver Injury Dietary Supplements |
description |
Background & aims: Ashwagandha (Withania somnifera) is widely used in Indian Ayurvedic medicine. Several dietary supplements containing ashwagandha are marketed in the US and Europe, but only one case of drug-induced liver injury (DILI) due to ashwagandha has been published. The aim of this case series was to describe the clinical phenotype of suspected ashwagandha-induced liver injury. Methods: Five cases of liver injury attributed to ashwagandha-containing supplements were identified; three were collected in Iceland during 2017-2018 and two from the Drug-Induced Liver Injury Network (DILIN) in 2016. Other causes for liver injury were excluded. Causality was assessed using the DILIN structured expert opinion causality approach. Results: Among the five patients, three were males; mean age was 43 years (range 21-62). All patients developed jaundice and symptoms such as nausea, lethargy, pruritus and abdominal discomfort after a latency of 2-12 weeks. Liver injury was cholestatic or mixed (R ratios 1.4-3.3). Pruritus and hyperbilirubinaemia were prolonged (5-20 weeks). No patient developed hepatic failure. Liver tests normalized within 1-5 months in four patients. One patient was lost to follow-up. One biopsy was performed, showing acute cholestatic hepatitis. Chemical analysis confirmed ashwagandha in available supplements; no other toxic compounds were identified. No patient was taking potentially hepatotoxic prescription medications, although four were consuming additional supplements, and in one case, rhodiola was a possible causative agent along with ashwagandha. Conclusions: These cases illustrate the hepatotoxic potential of ashwagandha. Liver injury is typically cholestatic or mixed with severe jaundice and pruritus, but self-limited with liver tests normalizing in 1-5 months. |
author2 |
Medicine, School of Medicine |
format |
Article in Journal/Newspaper |
author |
Björnsson, Helgi K. Björnsson, Einar S. Avula, Bharathi Khan, Ikhlas A. Jonasson, Jon G. Ghabril, Marwan Hayashi, Paul H. Navarro, Victor |
author_facet |
Björnsson, Helgi K. Björnsson, Einar S. Avula, Bharathi Khan, Ikhlas A. Jonasson, Jon G. Ghabril, Marwan Hayashi, Paul H. Navarro, Victor |
author_sort |
Björnsson, Helgi K. |
title |
Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
title_short |
Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
title_full |
Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
title_fullStr |
Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
title_full_unstemmed |
Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network |
title_sort |
liver injury due to ashwagandha. a case series from iceland and the u.s. drug-induced liver injury network |
publisher |
Wiley |
publishDate |
2020 |
url |
https://hdl.handle.net/1805/29858 |
geographic |
Indian |
geographic_facet |
Indian |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
PMC |
op_relation |
10.1111/liv.14393 Liver International Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829. doi:10.1111/liv.14393 https://hdl.handle.net/1805/29858 |
op_rights |
Publisher Policy |
op_doi |
https://doi.org/10.1111/liv.14393 |
container_title |
Liver International |
container_volume |
40 |
container_issue |
4 |
container_start_page |
825 |
op_container_end_page |
829 |
_version_ |
1809916337948983296 |